Categorizing immunotherapy resistance mechanisms in non-small cell lung cancer: how can we perform better?
The introduction of immune checkpoint inhibitors (ICI) has revolutionized the treatment of many solid tumors including advanced non-small cell lung cancer (NSCLC) without targetable driver alterations. Unfortunately, the majority of patients with NSCL…